Telomerase Activity as a Marker For Mobilization Quality

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Rabin Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT01555359
First received: March 13, 2012
Last updated: March 14, 2012
Last verified: January 2012
  Purpose

Autologous hematopoietic cell transplantation (HCT) is a treatment strategy used as advanced line therapy for different malignancies, mainly hematological. Its main advantage lies in the ability to provide hematologic and immune rescue after high dose chemotherapy therapy. The first requirement of a successful transplantation is recruitment of sufficient amount of cells. This is achieved by mobilizing CD34+ stem cells from the bone marrow to the peripheral blood, by G-CSF priming, and then harvesting the cells from the peripheral blood at the right timing by means of apheresis. Currently, the decision on the optimal collection timing is based on the pre-collection CD34 cells blood concentrations.

The investigators goal is to investigate whether telomerase, the telomere elongation enzyme, which constitutionally and solely expressed in progenitor cells, is correlated with collection and post HCT engraftment characteristics.

The investigators will collect blood from patients when starting GCSF and on the day of planned apheresis. Pearson correlation test will be used to correlate between telomerase activity in the samples and with collection and engraftment characteristics.


Condition
Lymphoma
Multiple Myeloma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Telomerase Activity Of CD34+ Cells - Marker For Mobilization Quality And Predictor For Engraftment After Autologous Hematopoietic Cell Transplantation

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Biospecimen Retention:   Samples Without DNA

Whole blood


Estimated Enrollment: 50
Study Start Date: February 2012
Estimated Study Completion Date: February 2013
Groups/Cohorts
Patients undergoing stem cell collection

Detailed Description:

Autologous hematopoietic cell transplantation (HCT) has revolutionized the curative approach to a number of malignancies by providing hematopoietic and immune rescue after high dose cytoreductive therapy. In cases of residual disease, patients are usually treated with chemotherapy to repress the disease, thereafter G-CSF injections are given serially to encourage stem cell proliferation in the bone marrow and mobilization of the stem/progenitor cells to the peripheral blood. Another approach, usually utilizes in myeloma patients is the administration of G-CSF in steady state (without administration of chemotherapy) and consequently collection of the CD34+ cells.

The minimum number of CD34+ cells threshold requires for HCT is currently defined as 2 x 10^6/kg. However, the optimal dose in terms of engraftment may be even higher (>5x10^6/kg), especially when platelet recovery is considered.

In clinical practice, the right timing for collection is decided upon measurement of CD34, a membrane glycoprotein of progenitors and stem-cells. CD34 levels are measured in the expected maximal effect of the G-CSF priming, and accordingly the collection is scheduled. Practically, if the circulating CD34+cell count is ≥20/μL, 90% of collections performed the following day would be expected to yield ≥2.0x106 CD34+cells/kg (Gordon, BMT 1997). However, in cases higher doses of CD34+ cells are required (e.g. for tandem HCT), CD34+ threshold may not be sufficient to determined collection yield.

G-CSF based mobilization regimens have a 5-30% failure rate amongst patients, however in patients with risk factors, up to 60% of the patients are failed to mobilize. Poor mobilization has significant consequences for the patient with potential loss of transplantation as a treatment option. Repeated attempts at mobilization increase resource utilization, morbidity and patient inconvenience. Therefore attempts to identify patients who would mobilize poorly are of clinical significance.

Human telomerase, a unique ribonucleoprotein complex, is inactive in normal somatic cells but present in high levels in more than 90% of all malignancies. The enzyme, synthesize new telomeric repeats at the 3' ends of chromosomes.

As oppose to other normal cells, stem cells are unique in that they carry active telomerase which provides them with longer life span. Previous study from our lab showed that in patients and healthy donors, the administration of GCSF was associated with a 14th fold increase of telomerase activity levels in peripheral blood CD34+ cells.

Working hypothesis:

Telomerase activity in mobilized stem cells is correlated with both the absolute number of the collected cells and with the quality of the future engraftment after high dose therapy and HCT

Specific aims:

  1. To investigate the correlation between telomerase activity of CD34+ cells in the day of collection and the total number of collected CD34+ cells in a cohort of 50 patients undergoing stem cells mobilization and collection.
  2. To explore the association between telomerase activity of CD34+ cells and the engraftment characteristics (time to platelets>50000/microL, time to platelets>150000/microL, time to neutrophils>500/microL, time to neutrophil>2000/microL).
  3. To develop an algorithm based on CD34+ cells levels and CD34+ telomerase activity, both measured on the day of collection, that can serve as predictor for the total number of CD34+ cells to be collected.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients undergoing stem cell mobilization and collection

Criteria

Inclusion Criteria:

  1. Age >18 years
  2. Patient is candidate for stem cell mobilization and collection
  3. Patient is willing to sign an informed concent

Exclusion Criteria:

  1. Age <18 years
  2. Patient not willing or not in a state to sign an informed concent
  3. Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01555359

Contacts
Contact: Ron Ram, M.D. 0504065621 ronra@clalit.org.il

Locations
Israel
BMT Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital Recruiting
Petah-Tiqva, Israel, 49100
Contact: Ron Ram, M.D.    972-3-9378116    ronra@clalit.org.il   
Principal Investigator: Ron Ram, M.D.         
Sub-Investigator: Moshe Yeshurun, M.D.         
Sponsors and Collaborators
Rabin Medical Center
Investigators
Principal Investigator: Ron Ram, M.D. BMT Unit, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital
  More Information

Publications:
Responsible Party: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT01555359     History of Changes
Other Study ID Numbers: HCT-TEL-001
Study First Received: March 13, 2012
Last Updated: March 14, 2012
Health Authority: Israel: Institutional Review Board

Additional relevant MeSH terms:
Lymphoma
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders

ClinicalTrials.gov processed this record on July 31, 2014